SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

Renewed tariff threats against European allies, stemming from the Greenland situation, are currently dominating market discourse for SPY and impacting futures. While some investors anticipate a significant market pullback, many view any dip as a familiar "buy the dip" opportunity, expecting a rapid recovery as markets have previously navigated similar geopolitical "drama". The community is actively debating the potential for broader trade implications and forthcoming economic and political developments to shape near-term direction.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as renewed tariff threats regarding Greenland trigger market volatility, with the community sharply divided between those anticipating a significant correction and "buy the dip" proponents. Investors are weighing escalating geopolitical tensions and rising treasury yields against historical market resilience and expectations for a robust tech earnings season.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Shares of Trump Media & Technology Group are trending as recent statements from Donald Trump regarding Greenland's acquisition and associated tariff threats on European nations spark intense debate. The community is actively discussing the geopolitical implications and potential market volatility, with sentiment largely driven by reactions to these prominent political headlines.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is experiencing significant recent volatility and a notable pullback, sparking intense community debate. While bulls highlight strong fundamental growth from its AI-powered AXON platform and recent analyst upgrades as a "buy the dip" opportunity, bears point to circulating short report rumors and broader ad-tech sector weakness, alongside discussions of options market dynamics, as reasons for the sharp decline. This creates a highly active discussion about the stock's near-term direction ahead of upcoming earnings.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF (UVIX) is seeing intense discussion as escalating geopolitical tensions, from US actions in Venezuela and Greenland to EU tariff disputes and potential escalations with Iran and China, fuel expectations for a market-wide fear spike. Traders are actively positioning for a major upward move in volatility, leveraging UVIX for short-term hedges while widely acknowledging its pronounced decay characteristics make it unsuitable for extended holding.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high investor enthusiasm following international approvals for its Anktiva treatment in both lung and bladder cancers, notably a first-in-world non-chemo combo for lung cancer from Saudi Arabia. This significant progress, coupled with reported substantial revenue growth, is generating widespread community discussion about the company's transformative potential in oncology and fueling considerable short squeeze speculation due to high short interest. Investors are closely monitoring further global regulatory developments and anticipating a paradigm shift in cancer treatment as Dr. Patrick Soon-Shiong actively promotes the company's innovative "BioShield" platform.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is drawing attention following recent developments in its pipeline, including the acquisition of VLX-1005 and ongoing progress for its lead anticoagulant, tecarfarin, notably through a collaboration with Abbott for pivotal trials. Community discussion is split between excitement over its potential in treating rare cardiovascular conditions and concerns regarding dilution and the need for substantial financing for upcoming clinical milestones. Its ultra-low float is also a key talking point, contributing to observed volatility and the potential for significant price action.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MULN CRYPTO is trending due to a mix of strong skepticism and active promotion, with many users questioning its legitimacy and connection to the controversial Mullen Automotive stock, often cited as a past "scam." While some in the community label it "garbage" and warn of further losses, a dedicated segment is actively calling for accumulation and anticipating significant price surges for the "Mullen Army" token on the Solana network.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF ($VIXY) is trending as renewed discussions around escalating geopolitical tensions, potential government actions like tariffs, and broader market overvaluation fuel expectations for increased volatility. The community is actively debating whether current market conditions warrant a substantial spike in volatility, with many viewing $VIXY as a critical hedge against potential market shifts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Natural Gas prices are surging dramatically, driven by widespread forecasts for an intense Arctic blast across the US, with many in the community anticipating a significant short squeeze and a substantial gap-up for BOIL when markets open. Traders are actively debating whether these substantial gains will hold, given the highly volatile nature of leveraged natural gas ETFs like BOIL.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders

SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of Shareholders SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates HSII, VECO, CMA, TRML on Behalf of...

NVS Reports Positive Late-Stage Data on Kidney Disease Drug 

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

NVS to Acquire TRML, Add Phase III Cardiovascular Drug to Pipeline 

Novartis is set to acquire Tourmaline Bio for $1.4B, adding late-stage anti-IL-6 candidate pacibekitug to its cardiovascular pipeline.

Shares of Tourmaline Bio (TRML) jumped 58% in the pre-market session on Tuesday after Novartis (NVS) announced that it has agreed to acquire the smaller biopharmaceutical firm.Under the <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novartis.com/news/media-releases/novartis-acquire-tourmaline-bio-complementing-cardiovascular-pipeline-pacibekitug-treatment-atherosclerotic-cardiovascular-disease-ascvd">deal</a>, Novartis will commence a tender offer to purchase all outstanding shares of Tourmaline common stock through an indirect wholly owned unit. The deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price and values the company at about $1.4 billion on a fully diluted basis. Following the closing of the tender offer, the unit will merge with Tourmaline, and the company will become an indirect wholly owned subsidiary of Novartis.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/TRML">TRML stock</a> jumped from ‘bearish’ to ‘extremely bullish’ over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/NVS">NVS stock</a> fell from ‘Neutral’ to ‘Bearish territory, while message volume rose from ‘low’ to ‘normal’ levels.Novartis stated that the acquisition includes Tourmaline’s Pacibekitug being developed as a treatment option for atherosclerotic cardiovascular disease or the build-up of fats, cholesterol, and other substances in and on the artery walls. Pacibekitug complements Novartis’ cardiovascular strategy, the company said, while noting that with mid-stage trials of Pacibekitug already well-advanced, the company will acquire a late-stage-ready asset."Inflammation is a major driver of cardiovascular disease, and the team at Tourmaline has made significant progress with this asset. We are excited to bring Pacibekitug into the Novartis portfolio and collaborate with the Tourmaline team to advance its development as we diversify our efforts in cardiovascular care," said Shreeram Aradhye, Chief Medical Officer of Novartis. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; The transaction has been unanimously approved by the Board of Directors of both companies. It is expected to close in the fourth quarter of 2025, subject to the satisfaction or waiver of customary closing conditions. Until the transaction is closed, the two companies will continue to operate as separate, independent entities, Novartis said.TRML stock is up by 49% this year, while NVS stock gained over 32%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-launches-ai-machine-learning-platform-called-tunelab/chwKTzARdsU">Eli Lilly Launches AI, Machine Learning Platform Called TuneLab For Biotech Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 

Equity

Novartis has announced that it has agreed to acquire the biopharmaceutical firm, and the deal price of $48 per share presents a premium of nearly 59% to Tourmaline’s last closing price. 


Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's  What You Should Know

The consensus price target hints at a 151% upside potential for Tourmaline Bio, Inc. (TRML). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Tourmaline Bio, Inc. is a late-stage clinical biotechnology company, which engages in the development of medicines for patients with life-altering immune diseases. It offers the TOUR006. The company was founded by Sandeep Kulkarni on September 17, 2021 and is headquartered in New York, NY.

TRML
Tourmaline Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest TRML News

TRMLTourmaline Bio Inc